In a similar vein, the REPOSIT study attempted to investigate ctDNA mutational markers of resistance to targeted treatment with BRAF/MEK inhibition in unresectable stage IIIc/IV melanoma [108]. This evidence concerns the gene MAP2K7 and melanoma.